טוען...
The need for additional genetic markers for MDS stratification: what does the future hold for prognostication?
Myelodysplastic syndromes (MDS) constitute a heterogeneous group of clonal hematopoietic disorders. Metaphase cytogenetics (MC) has been the gold standard for genetic testing in MDS, but it can detect clonal cytogenetic abnormalities in only 50% of cases. New karyotyping tests include fluorescence i...
שמור ב:
| הוצא לאור ב: | Expert Rev Hematol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4535709/ https://ncbi.nlm.nih.gov/pubmed/23373781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/ehm.12.67 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|